Metsera (MTSR) & Its Rivals Critical Comparison

Metsera (NASDAQ:MTSR) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its competitors? We will compare Metsera to related businesses based on the strength of its analyst recommendations, dividends, risk, earnings, institutional ownership, profitability and valuation.

Institutional & Insider Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 13.4% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Metsera and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metsera	N/A	-$209.13 million	-11.16
Metsera Competitors	$968.43 million	-$41.26 million	10.00

Metsera’s competitors have higher revenue and earnings than Metsera. Metsera is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Metsera and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metsera	1	3	4	0	2.38
Metsera Competitors	6288	12375	38057	1201	2.59

Metsera currently has a consensus price target of $55.75, indicating a potential downside of 20.92%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 55.04%. Given Metsera’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Metsera has less favorable growth aspects than its competitors.

Profitability

This table compares Metsera and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metsera	N/A	-121.12%	-53.54%
Metsera Competitors	-906.16%	-572.54%	-29.84%

Summary

Metsera competitors beat Metsera on 10 of the 12 factors compared.

About Metsera

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.